Latest Opexa Therapeutics Stories
PHILADELPHIA, Nov. 26, 2012 /PRNewswire/ -- RRY Publications LLC today announced that the use of stem cell therapies in 2012 significantly exceeded forecasts which were originally presented at the February 2012 New York Stem Cell Summit. Said Robin Young, stem cell industry analyst and host of the New York meeting: "The range and scope of stem cell therapeutic use in the United States grew much faster than we'd forecasted earlier this year. Virtually all of the increases we're...
CARLSBAD, Calif., Sept. 27, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced it has received FDA 510(k) clearance for its OpTmizer(TM) CTS(TM) T-Cell Expansion Tissue Culture Medium - a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials. The OpTmizer(TM) CTS(TM) T-Cell Expansion Tissue Culture Medium is intended for human ex vivo...
HOUSTON, Aug. 2, 2012 /PRNewswire/ -- Celltex Therapeutics Corporation, a leader in regenerative medicine services, today announced the appointments of Andrea Ferrenz, Executive Vice President, Legal Counsel, and Jane Shen Young, Manufacturing Research Scientist. Ferrenz's primary responsibility will be overseeing operations, including compliance with federal and state regulatory agencies. Young's primary responsibility will be research and development of manufacturing processes and...
NATICK, Mass., Nov. 25, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce that its wholly owned subsidiary Regenocell, Ltd. is in the final stages of negotiations with several potential new distributors. It is anticipated that one or more will be finalized by year end and begin purchasing cell processing services in the near term. This will have a beneficial impact on revenues generated by the cell...
NATICK, Mass., July 29, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce it is planning to open another state of the art facility in Panama for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy. The Company's treatment for congestive heart failure when cleared for importation into Panama will be administered at the Hospital Sante Fe. Panama is...
NATICK, Mass., July 18, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) -announced that it will be featured in an upcoming segment of Profiles with Terry Bradshaw. Profiles follows fascinating business stories to give viewers first-hand insights from entrepreneurs of various industries. As part of the Company's segment, viewers will be educated about the unique individualized medicine and technology the Company is utilizing as a treatment for congestive heart failure and...
NATICK, Mass., July 8, 2011 /PRNewswire/ -- RegenoCELL Therapeutics, Inc. (OTCBB: RCLL) , a leader in adult stem cell therapy, is pleased to announce the opening of another state of the art facility in Greece for patients to be treated for congestive heart failure and peripheral artery disease with its autologous stem cell therapy. The Company's treatment for congestive heart failure is administered at the Metropolitan Hospital in Athens, which is part of the PERSEUS Heath Care Group....
ALLENDALE, N.J., and NEW YORK, May 3, 2011 /PRNewswire/ -- Progenitor Cell Therapy, LLC (PCT), an internationally recognized cell therapy services and development company and a wholly-owned subsidiary of NeoStem, Inc (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, has expanded its business through new contract and contract extensions. NeoStem believes its strategic acquisition of PCT earlier this year is being validated each time the...
SAN FRANCISCO, April 20, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) ("the Company")and maintains its twelve month target price of $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "According to the Company, Opexa's lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is scheduled to advance into a pivotal Phase 3 clinical study in the...
JUPITER, Fla., April 13, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ) has announced that Francisco J. Silva has been hired as its Vice President of Research and Development. Mr. Silva is expected to play a key role in leading the company's laboratory biological tool initiative and by developing a product portfolio targeted to meet the demands of large pharmaceutical companies' drug discovery and development platforms. Since 2007, Mr. Silva has served as CEO of DV Biologics LLC,...
